[APASL2014]Controlling hepatitis B:Will we ever eradicate it?——Interview with Dr.Stephen Locarnini
The most important message that we have at the moment in terms of gauging where HBV is going in the region is， well， you might have heard of the recent diseased burden studies. There have been several follow up to the Global Burden of Disease study， it’s called. And up until very recently， everyone has been fobbing off chronic hepatitis and liver disease and liver cancer basically saying well， a vaccine is coming and if the HBV vaccine is here， then treatments will come for HCV so our priority is no viral hepatitis.
阅读数：181详细阅读>>
[APASL2014]Progress and Prospect of the Prevention and Control of Hepatitis——Interview with Mr.Charles Gore
The Alliance has been concentrating on trying to get countries to introduce viral hepatitis strategies. I spent a large part of the last year visiting a lot of countries. At the World Health Assembly last year， we decided to try and put together a group of supporting countries and as a result of that， they decided that it was time to draft new resolutions. So we have been working throughout last year on drafting a new WHA resolution. Although the one in 2010 was a bit of a landmark in that there hadn’t been one on viral hepatitis per se ever before， progress had been really slow. So we worked with a few countries.
阅读数：550详细阅读>>
[APASL2014]Asia-Pacific Region: The Epicentre of Liver Disease——Interview with Prof.Darrell Crawford
It’s a new era in a number of ways. The first is the emergence and use of new antiviral agents for hepatitis C. That is probably what most people would think is the meaning of the subtitle because of these developments and their improvements in treatment response to these agents as well as their likely increasing availability in the world， and particularly the Asia-Pacific region， in the next twelve months. But there is also a more intuitive sense to the title. In my opening address， I will talk about the Asia-Pacific region as an emerging force in global hepatology.
阅读数：245详细阅读>>
[APASL2014]Encouraging Weight Loss in NAFLD——Interview with Dr.Ingrid Hickman
The short answer is yes. We can agree that weight loss， specifically fat loss， is important in preventing NAFLD. The problem is that NAFLD is a complex condition. A typical patient may have diabetes or high blood pressure or cardiovascular disease as well as their liver disease. An ideal treatment for NAFLD will target all of those conditions and fat loss certainly does this. This strategy will improve glucose control in diabetes， reduce blood pressure， reduce steatosis， and will certainly reduce fibrosis.
阅读数：113详细阅读>>
[APASL2014]HBIG Is Being Phased Out!——Interview with Prof.James Fung
Currently there is no single defining prophylactic protocol for antiviral therapy after liver transplantation because of all of the new antiviral therapies that have become available in the last four or five years. Different centers have adopted different regimens. If you go back the best part of a decade， I think the most widely accepted protocol has been the combination of HBIG and lamivudine.
阅读数：132详细阅读>>
[APASL2013]Curing HBV:A Light at the End of the Tunnel? ——interview with Prof. Massimo Levrero
Hepatology Digest: We are able to achieve viral suppression with the use of NAs and IFN in chronic hepatitis B infected patients. However， while many benefit from antiviral therapy in clinical practice， there are long-term problems with therapy that include side effects， low response rates， and an inability to eradicate the cccDNA in hepatocytes. With regard to new novel targets for therapy， what parts of the HBV replication process should research be focusing on?
阅读数：829详细阅读>>
